探花精选

Per Svenningsson

Per Svenningsson

Professor/Senior Physician
Visiting address: BioClinicum聽J5:20, Akademiska str氓ket 1, Karolinska universitetssjukhu, 17164 Solna
Postal address: K8 Klinisk neurovetenskap, K8 Neuro Svenningsson, 171 77 Stockholm
Part of:

About me

  • Per Svenningsson, MD, PhD, is a Professor of Neurology and a PI at the Department of Clinical Neuroscience, 探花精选. He is also a Senior Physician at the Karolinska University Hospital.

Articles

  • Journal article: CELL DEATH & DISEASE. 2025;16(1):693
    Gerlach J; Pireddu P; Zhang X; Wetzel S; Mennuni M; Milenkovic D; Nolte H; da Silva Rodrigues F; Branzell N; Kaya I; Villegas RG; Rubalcava-Gracia D; Alsina D; Feederle R; Andren PE; Langer T; Svenningsson P; Filograna R
  • Article: ANNALS OF NEUROLOGY. 2025;98(4):762-763
    Alm V; Thonberg H; Svenningsson P; Paucar M
  • Journal article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2025
    Sturchio A; Paslawski W; Khosousi S; Markaki I; Nalls MA; Singleton AB; Iwaki H; Svenningsson P
  • Journal article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025;26(18):9213
    Laffita-Mesa JM; Paucar M; Svenningsson P
  • Article: BRITISH JOURNAL OF PHARMACOLOGY. 2025
    Li T; Vukojevic V; Oasa S; Bai Y; Yang Y; Li H; Tang Y; Terenius L; Hokfelt T; Svenningsson P; Xu Z-QD
  • Journal article: CHEMISTRY-METHODS. 2025
    Vallianatou T; Balestri LJI; Nilsson A; Zhang X; Svenningsson P; Odell LR; Andren PE; Shariatgorji R
  • Journal article: SLEEP MEDICINE CLINICS. 2025;20(3):259-268
    Gomez-Ocadiz R; Svenningsson P
  • Journal article: NEUROTHERAPEUTICS. 2025;22(5):e00690
    Strempfl K; Zattoni M; Mrowetz H; Unger MS; Schoerghofer N; Altendorfer B; Neddens J; Flunkert S; Hutter-Paier B; He Y; Wallin J; Poupardin RW; Pietrantonio F; Paiement N; Zerbe H; Felder T; Svenningsson P; Aigner L
  • Journal article: NPJ PARKINSONS DISEASE. 2025;11(1):258
    Kaya I; Vallianatou T; Nilsson A; Bjarterot P; Shariatgorji R; Svenningsson P; Bezard E; Andren PE
  • Journal article: MOVEMENT DISORDERS CLINICAL PRACTICE. 2025
    Fasano A; Spanaki C; Gurevich T; Jech R; Svenningsson P; Szasz J; Vela-Desojo L; Simu M; Bergmann L; Saad A; Parra JC; Kovacs N
  • Journal article: NEUROIMAGE-CLINICAL. 2025;48:103857
    Olsson C; Skorpil M; Svenningsson P; Moreno R
  • Article: MOVEMENT DISORDERS. 2025;40(8):1551-1560
    Wiesman AI; Vinding MC; Tsitsi P; Svenningsson P; Waldthaler J; Lundqvist D
  • Journal article: JOURNAL OF ALZHEIMERS DISEASE. 2025;:13872877251360404
    Chong JR; Hye A; Boada M; Svenningsson P; Fladby T; Aarsland D
  • Journal article: JCI INSIGHT. 2025;10(13):e188413
    Nuber S; Hsiang H; Keewan E; Moors TE; Reitz SJ; Tiwari A; Ho GPH; Su E; Hahn W; Adom M-A; Pathak R; Blizzard M; Kim S; Ko HS; Zhang X; Svenningsson P; Selkoe DJ; Fanning S
  • Article: NPJ PARKINSONS DISEASE. 2025;11(1):170
    Andreasson M; Paslawski W; Terkelsen AJ; Samuelsson K; Zetterberg H; Blennow K; Karlsson P; Svenningsson P
  • Journal article: ANALYTICAL CHEMISTRY. 2025;97(21):10957-10961
    Shariatgorji R; Niehues M; Nilsson A; Angerer T; Stroth N; Paslawski W; Jabre S; Svenningsson P; Andren PE
  • Journal article: LANCET NEUROLOGY. 2025;24(6):548-556
    Winston G; Kharas N; Svenningsson P; Jha A; Kaplitt MG
  • Article: PCN REPORTS. 2025;4(2):e70123
    Sturchio A; Svensson JE; Tiger M; Moren AF; Varrone A; Svenningsson P; Okubo Y; Tateno A
  • Journal article: PCN REPORTS. 2025;4(2)
    [18F]FE鈥怭E2I PET is a diagnostic tool in dementia with Lewy bodies
    Sturchio A; Svensson JE; Tiger M; Mor茅n AF; Varrone A; Svenningsson P; Okubo Y; Tateno A
  • Article: MOVEMENT DISORDERS. 2025;40(6):1134-1142
    Svenningsson P; Odin P; Bergquist F; Wirdefeldt K; Nyholm D; Andreasson M; Markaki I; Johansson AC; Jergil M; Jankosky C; Varney MA; Herbrecht F; Johnson SA; Newman-Tancredi A
  • Show more

All other publications

  • Preprint: MEDRXIV. 2025
    Helson P; Benyahiya E; Manikandan S; Waldthaler J; Vinding M; Lundqvist D; Svenningsson P; Mitra D; Kumar A
  • Preprint: BIORXIV. 2025
    Lyu G; Garcia-Swinburn R; Kreutzmann J; Xiong A; Kojima R; Abaurre C; Tremolanti C; Gellhaar S; Uhl茅n P; Svenningsonn P; Castelo-Branco G; Dagliyan O; Salto C; Arenas E
  • Preprint: BIORXIV. 2025
    Chen Y; Kahlous NA; Saarinen M; Conesa SP; Svenningsson P; Delemotte L; Carlsson J
  • Preprint: BIORXIV. 2025
    Chen Y; Saarinen M; Naraine A; Carlsson J; Svenningsson P; Delemotte L
  • Preprint: MEDRXIV. 2025
    Olsson C; Skorpil M; Svenningsson P; Moreno R
  • Preprint: BIORXIV. 2025
    Ribe E; Ghosh A; Paslawski W; Savory K; Ballard C; Morin P; Cash D; Hirth F; Williams G; Svenningsson P; Aarsland D; Siow RCM; Killick R
  • Preprint: BIORXIV. 2025
    Bj盲rterot P; Nilsson A; Shariatgorji R; Vallianatou T; Kaya I; Svenningsson P; K盲ll L; Andr茅n P
  • Preprint: MEDRXIV. 2024;MEDRXIV
    Wiesman AI; Vinding MC; Tsitsi P; Svenningsson P; Waldthaler J; Lundqvist D
  • Review: NATURE REVIEWS NEUROLOGY. 2024;20(11):671-684
    Friberg S; Lindblad C; Zeiler FA; Zetterberg H; Granberg T; Svenningsson P; Piehl F; Thelin EP
  • Review: MOVEMENT DISORDERS. 2024;39(10):1697-1709
    Gibson LL; Weintraub D; Lemmen R; Perera G; Chaudhuri KR; Svenningsson P; Aarsland D
  • Preprint: BIORXIV. 2024
    Gerlach J; Pireddu P; Zhang X; Wetzel S; Mennuni M; Milenkovic D; Nolte H; Branzell N; Kaya I; Villegas RG; Rubalcava-Gracia D; Alsina D; Feederle R; Andr茅n P; Langer T; Svenningsson P; Filograna R
  • Review: FRONTIERS IN PHARMACOLOGY. 2024;15:1450493
    Pietrantonio F; Serreqi A; Zerbe H; Svenningsson P; Aigner L
  • Editorial comment: CURRENT OPINION IN NEUROLOGY. 2024;37(4):392-393
    Svenningsson P
  • Conference publication: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2024;2024:1-6
    Ymeri G; Maus B; Wassenburg M; Olsson CM; Svenningsson P; Salvi D
  • Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024;25(13):7102
    Skrahin A; Horowitz M; Istaiti M; Skrahina V; Lukas J; Yahalom G; Cohen ME; Revel-Vilk S; Goker-Alpan O; Becker-Cohen M; Hassin-Baer S; Svenningsson P; Rolfs A; Zimran A
  • Letter: TRANSLATIONAL NEURODEGENERATION. 2024;13(1):31
    Appleton E; Khosousi S; Ta M; Nalls M; Singleton AB; Sturchio A; Markaki I; Paslawski W; Iwaki H; Svenningsson P
  • Review: JOURNAL OF PARKINSONS DISEASE. 2024;14(4):657-666
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
  • Letter: MOVEMENT DISORDERS. 2024;39(6):1077
    Paucar M; Nilsson D; Engvall M; Laffita-Mesa J; Wedell A; Svenningsson P
  • Editorial comment: MOVEMENT DISORDERS. 2024;39(6):929-933
    Outeiro TF; Kalia LV; Bezard E; Ferrario J; Lin C-H; Salama M; Standaert DG; Taiwo L; Takahashi R; Vila M; Mollenhauer B; Svenningsson P
  • Editorial comment: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2024;460:123020
    Sennfalt S; Gustavsson P; Malmgren H; Gilland E; Almqvist H; Oscarson M; Engvall M; Bjorkhem I; Nilsson D; Lagerstedt-Robinson K; Svenningsson P; Paucar M
  • Show more

Grants

  • Swedish Research Council
    1 January 2024 - 31 December 2026
    Parkinson鈥檚 disease and related disorders are the second most common neurodegenerative diseases. Parkinsonian disorders present with similar symptoms at their onset. The diagnosis, which is based on clinical criteria and follow-up, is challenging. An uncertain or wrong diagnosis may lead to inappropriate treatment and unwanted side effects for the individual patient and聽 increased costs for the healthcare system. Early, precise diagnosis is crucial聽for the development of treatments targeting molecular mechanisms of underlying disease.The aim of the present work is to identify characteristic patterns of cerebral blood flow聽(CBF) and their association with dopamine transporter (DAT) availability in parkinsonian disorders. This will be used to聽develop methods for precise differential diagnosis with PE2I positron emission tomography (PET) and supervised machine learning (ML).聽18F-FE-PE2I PET/CT scans providing both CBF and DAT availability from a single scan will be acquired in a cohort of at least 2500 patients from five Swedish university hospitals and will, together with comprehensive clinical diagnosis, be used to train ML-based classification.The project will result in a more precise method for differential diagnosis of parkinsonian disorders that will be available beyond specialized academic centres. It will further increase understanding of parkinsonism, support appropriate treatment in individual patients, and provide improved imaging biomarkers for drug development.
  • Swedish Research Council
    1 January 2023 - 31 December 2025
    The aim of this project is to identify the alterations in the major source of noradrenaline in the brain, the locus coeruleus, and establish whether these alterations can detect Alzheimer鈥檚 disease and Parkinson鈥檚 disease at an early stage. We will use a non-invasive technique called magnetization transfer ratio to measure the locus coeruleus in four different cohorts. Our results will establish whether changes in the locus coeruleus precede abnormalities in cerebrospinal fluid, plasma and imaging markers in the course of these neurodegenerative diseases. Moreover, we will establish whether different subregions within the locus coeruleus can predict different clinical symptoms and clinical trajectories, being useful to create a precision medicine approach that takes into account individual patient characteristics. Finally, we will use the locus coeruleus as an outcome measure in current multi-domain clinical trials to identify patients that are most likely to benefit from treatment. This will also allow us to obtain information on how new preventive therapies might be created to boost the neuroprotective functions of the locus coeruleus against pathological protein accumulation. We are confident that we can achieve these aims in a timely manner due to our excellent team of experts and our access to all the necessary equipment and a unique infrastructure that will allow a fast translation of our findings to clinical trials.
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    The aim of this project is to elucidate L-DOPA-induced dyskinesia (LID) in Parkinson鈥檚 disease (PD) by clarifying the pathophysiological mechanisms involved, which are currently unknown although LID is one of the most difficult problems facing patients with PD. We will use innovative matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to simultaneously image and quantify neurotransmitter and neuropeptide systems, endogenous metabolites and lipids, and proteins directly in brain tissue sections. Achievement of this aim will be facilitated by access to a biobank of brain tissues of non-human primates providing unprecedentedly comprehensive coverage of an LID model and controls, neurotoxic and genetic rodent PD models, as well as human brains and cerebrospinal fluid. We will develop methodology for highly multiplex protein imaging by MALDI-MSI. To enable imaging of single cells directly in tissue sections we will increase the spatial resolution to &lt
    1 碌m by using deep learning technology. We will also design and synthesise chemical tools enabling imaging of hitherto undetectable endogenous substances in the samples, and apply pathway analysis to determine the signalling status of the cells, quantitatively, from measured expression levels of molecular species. Thus, the project will provide novel insights into the underlying mechanisms of LID (and PD), which may enable development of new therapy targets and/or clinically useful biomarkers.
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Parkinson鈥檚 disease (PD) is the fastest growing neurodegenerative disease, and the development of a disease-modifying therapy is the most important unmet goal in the therapy of PD. Preclinical and clinical studies have shown promising results of the anti-inflammatory agent聽 Montelukast in PD. We have now designed a multi-center, randomized, double-blind, placebo-controlled trial with Montelukast in PD.PICO Population: Diagnosis of PD. Males or Females. H&Y stage 鈮 2. 鈮35 and 鈮80 years of age. Signed informed consent to participate in the trial. Clinical diagnosis &lt
    4 years. Ability to self-administer the trial drug. 聽Intervention: 18 months of daily buccal Montelukast 2x30 mg.聽Control: Placebo. Primary outcome: Change of MDS-UPDRS motor score in OFF medication state at 18 months. Secondary outcomes are changes in effects on non-motor symptoms of Montelukast聽using MDS-NMSS and HADS. There is also a safety objective and several exploratory outcomes.Ninty patients with early-moderate PD in Stockholm,聽Lund, Uppsala, G枚teborg and London will be recruited. Ethical permits and MPA applications will be submitted in the beginning of 2023. Patient recruitment will start in April 2023 and the last patient follow-up will be in March 2026 followed by data analysis/reporting. The study is endorsed by the Swedish PD patientorganization and Cure Parkinson. If this聽RCT is successful and since Montelukast is repurposed, patients will soon benefit from the therapy.
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Life means combining motor-cognitive skills, e.g., walking, talking and navigating. Aging or neurological diseases, e.g., Parkinson鈥檚 disease (PD) compromises these skills needed for an independent life. It is uncertain which brain alterations lead to these difficulties and how to target these heterogenous motor-cognitive difficulties. Current treatments apply a "one-size-fits-all" approach, which needs to evolve towards personalized rehabilitation, reaching beyond a simple adaption to disease severity.Our multimodal project combines physiotherapy, neurology, psychology and neuroimaging to characterize motor-cognitive skills during complex walking, identify underlying brain alterations and subtype PD to inform a novel exercise approach for people with PD. This 5 years proposal has 4 stages: 1) Exploring brain alterations and links to the motor-cognitive skills in healthy and PD 2) PD subtyping using neuroimaging, motor, cognitive and clinical data 3) Characterization of exercise responsiveness in PD and 4) Development and testing of a personalized motor-cognitive exercise program. We combine novel techniques for data collection with in-depth analysis of existing data (EXPANd trial). The results will have an immediate application and clinical relevance for personalized rehabilitation in older and PD. There is no cure for PD yet, thus positive findings would revolutionize treatment, giving new hope to patients for a life with improved health, independence and higher quality.
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Background: The age standardised rate of yearly new cancer cases is 190/100 000 globally, by WHO. 30-40% of these will develop depression. There is currently no specific antidepressant treatment regime implemented in the cancer population. This is in spite of the specific needs given by concurrent cancer treatments, limited quality of life from the cancer per se and the often limited life expectancy from a cancer disease. A single dose of psilocybin combined with 3 hours of psychological support has shown rapid (within days) and long term (months or years) antidepressant effect in several small studies in different cancer populations. Large, well designed RCTs are still lacking, as is response predictors for treatment guidance. I am PI of the first RCT of psilocybin treament of depression in Sweden, expected to end randomisation in june 2022. CAPSI: 100 patients with cancer and depression will be randomised to psilocybin or active placebo (2:1) at 4 different regions in Sweden during 2024-2025. Primary end point is depressive symptoms 6 weeks post dose and follw up is 6 months. All subjects will undergo EEG and blood sampling, a subsample (n=50) will also undergo MEG and fMRI, and 25 of them also PET, in order to develop a EEG proxy response signature. Together with markers in blood we will develop a predictor model for psilocybin treatment response. All data will be used to motivate a phase three study with the same PICO and further development of the response markers.
  • Swedish Research Council
    1 January 2022 - 31 December 2027
    We propose an innovative interdisciplinary research environment to investigate the pathophysiology of dementia in Parkinson鈥檚 disease (PDD) and Lewy Body dementia (LBD). Based on the identified molecular fingerprints we will also develop diagnostic and prognostic wet biomarkers. PDD and LBD are difficult to diagnose in the clinic and no diagnostic test is available. Differentiation from parkinsonian plus syndromes and Alzheimer鈥檚 disease is a major challenge and will be examined. The research environment consists of a unique combination of spatial omics methodologies, i.e., spatial transcriptomics, -proteomics, and -mass spectrometry combined with state-of-the-art bioinformatic tools. We synthesise chemical tools to enable detection low-abundant potential biomarkers compatible with the spatial analysis of a particular imaging modality. Clinical samples are available from the Stockholm BioPark cohort and King鈥檚 College Dementia Brain biobank. First, we will examine a comprehensive set of cortical post-mortem brains from control, PD, PDD and LBD. The biomarker potential of pathologically relevant molecules will then be assessed in CSF and plasma from a cohort of 650 patients. We aim at stimulating the needed of collaborations in correlated spatial omics, promoting and disseminating its benefits, and paving the way for its technological advancement and implementation in the neurological field to ultimately impact on clinically unmet 探花精选 needs for PDD and LBD patients.
  • Swedish Research Council
    1 January 2021 - 31 December 2023
  • Swedish Research Council
    1 January 2020 - 31 December 2024
  • Knut and Alice Wallenberg Foundation
    1 January 2019 - 1 January 2024
  • Swedish Research Council
    1 January 2019 - 31 December 2022
  • Swedish Research Council
    1 January 2019 - 31 December 2022
  • Swedish Research Council for Health Working Life and Welfare
    1 December 2018 - 30 November 2024
  • Swedish Research Council
    1 December 2017 - 31 December 2022
  • VINNOVA
    3 July 2017 - 29 June 2018
  • Swedish Research Council
    1 January 2017 - 31 December 2020
  • Swedish Research Council
    1 January 2016 - 31 December 2019
  • Swedish Research Council
    1 January 2016 - 31 December 2019
  • European Research Council
    1 August 2015 - 31 January 2022
  • Swedish Research Council
    1 January 2015 - 31 December 2018
  • Show more

Employments

  • Professor/Senior Physician, Department of Clinical Neuroscience, 探花精选, 2021-
  • Senior Physician, 2016-

Degrees and Education

  • Doctor Of Philosophy, Department of Physiology and Pharmacology, 探花精选, 1998
  • University Medical Degree, 探花精选, 1996

Supervision

  • Supervision to doctoral degree

    • Behzad Iravani, Novel measure of olfactory bulb function in health and disease, , 2021
    • Lovisa Brodin, Parkinson's disease and Gaucher disease : focus on the GBA1 link, , 2024

News from KI

Events from KI